Selected studies with unconjugated antibodies in AML
EFS indicates event-free survival; HiDAC, high-dose cytarabine; IPSS, International Prognostic Scoring System; MLFS, morphologic leukemia-free state; ND, newly diagnosed; OS, overall survival; RFS, relapse-free survival; R/R, relapsed/refractory.
Sign In or Create an Account